Welcure Drugs and Pharmaceuticals Limited reported a net loss of ₹549.01 crore for the financial year ended March 31, 2026, a significant decline from the net profit of ₹217.01 lakh recorded in the previous year. The company's total revenue from operations for FY26 was ₹2,645.99 lakh. The standalone audited financial results were reviewed by the audit committee and approved by the board of directors at a meeting held on May 29, 2026.

The company reported a net loss of ₹4,986.14 lakh for the quarter ended March 31, 2026. Total revenue from operations for the quarter was ₹146.43 lakh. The equity share capital of the company stood at ₹12,359.40 lakh as of March 31, 2026, compared to ₹1,125.12 lakh in the previous year.

Financial Performance

The following table outlines the key financial metrics for the quarter and year ended March 31, 2026:

The company's reserves, excluding revaluation reserves, were reported at negative ₹2,657.37 lakh for the year ended March 31, 2026. The financial results were prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 and were filed with the stock exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

welcure drugs & pharmaceuticals has scheduled a meeting of its Board of Directors for Friday, May 29, 2026. The meeting will be held at the company's registered office to discuss and approve key financial documents for the fiscal year ending March 31, 2026.

Agenda for the Meeting

The primary agenda for the board meeting includes the consideration and approval of the audited financial results for the quarter and year ended March 31, 2026. Additionally, the board will take on record the audit report of the statutory auditors associated with these results.

Financial Statements Approval

The directors are also expected to consider and approve the audited financial statements for the year ended March 31, 2026. This encompasses the balance sheet as of that date, along with the statement of profit and loss, cash flow statement, and accompanying notes.

Regulatory Compliance

The intimation of the board meeting was made in compliance with Regulation 29(1)(a) and (e) of the SEBI (LODR) Regulations, 2015. The company confirmed that it is in the process of filing the corporate announcement in XBRL format within the stipulated time, which will subsequently be hosted on its official website.

The meeting notice, signed by Director Chintan Didawala Ganpat, was dispatched to BSE Limited on May 22, 2026.